Clinical Trials Directory

Trials / Completed

CompletedNCT04615572

Screening to Improve Survival in AL Amyloidosis

Status
Completed
Phase
Study type
Observational
Enrollment
35 (actual)
Sponsor
Tufts Medical Center · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.

Conditions

Timeline

Start date
2020-08-28
Primary completion
2023-07-06
Completion
2023-07-06
First posted
2020-11-04
Last updated
2024-10-28

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04615572. Inclusion in this directory is not an endorsement.

Screening to Improve Survival in AL Amyloidosis (NCT04615572) · Clinical Trials Directory